Pulling SEC filings + quote and writing the call…

Century Therapeutics, Inc.
Next earnings Aug 3, 2026 (before open) · consensus $-0.12 EPS
Last earnings -0.4% on 2026-05-13
Revenue grew 1556.8% YoY; but unprofitable (net margin -8.8%).
Century Therapeutics, Inc. shows $109M in FY2025 revenue (+1556.8% YoY), a -8.8% net margin, and -6.0% ROE.
Sources: SEC EDGAR (CIK 0001850119, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 9:48:46 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $5.20M | $2.23M | $6.59M | $109M |
| Gross profit | — | — | — | — | — |
| Operating income | -$94.9M | -$134M | -$147M | -$138M | -$17.3M |
| Net income | -$95.8M | -$131M | -$137M | -$127M | -$9.58M |
| Diluted EPS | -$2.96 | -$2.96 | -$2.30 | -$1.61 | -$0.14 |
| Net margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1072 tracked peers · median
Last 90 days: 0 open-market buys · 2 sales
| 2026-06-12 | Russotti Gregory See Remarks | Sell | 2.58K @ $2.23 | $5.77K |
| 2026-06-12 | Carr Douglas SVP Finance & Operations | Sell | 1.65K @ $2.23 | $3.69K |
| 2026-06-11 | Pfeiffenberger Brent President and CEO | Tax | 13.8K @ $2.24 | $31.0K |
| 2026-06-11 | Cowan Chad Chief Scientific Officer | Tax | 358.00 @ $2.24 | $801.92 |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.